Literature DB >> 21733966

Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.

Rosa Cremades1, Juan Carlos Rodríguez, Eduardo García-Pachón, Antonio Galiana, Montserrat Ruiz-García, Pilar López, Gloria Royo.   

Abstract

OBJECTIVES: To compare the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in the latent and exponential growth phases.
METHODS: Ciprofloxacin, levofloxacin and moxifloxacin were tested against 16 M. tuberculosis clinical isolates (4 resistant and 12 susceptible to fluoroquinolones) from Elche, Spain, isolated between 1992 and 2009. To study bactericidal activity, an inoculum of approximately 10(5) cfu of each isolate was cultured in Middlebrook 7H9 broth. The broth was previously acidified to pH 4.6 to obtain the microorganism in the stationary phase. Cultures with different concentrations (0.1 to 50 mg/L) of antibiotic and antibiotic-free controls were incubated for 48 h then plated onto Middlebrook 7H11 to detect bacterial killing. In all stages of the process the M. tuberculosis strain ATCC 41323 was included as a quality control to ensure reproducible results.
RESULTS: Moxifloxacin and levofloxacin were found to exhibit bactericidal activity at lower concentrations and against more strains in both the latent and the exponential growth phases compared with ciprofloxacin. The bactericidal activity of moxifloxacin was greater than that of levofloxacin against microorganisms in the exponential growth phase, but the opposite was true in the latent phase.
CONCLUSIONS: Our data confirm the usefulness of moxifloxacin in the treatment of tuberculosis and suggest that levofloxacin may be used as an alternative drug in the treatment of latent tuberculosis when it is not possible to use isoniazid. Based on the results presented, ciprofloxacin appears to be a poor choice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733966     DOI: 10.1093/jac/dkr281

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.

Authors:  Ju Young Lee; Hyun Jung Lee; Yong Kyun Kim; Shinae Yu; Jiwon Jung; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Tae Sun Shim; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.

Authors:  Seung Heon Lee; Kyung-Ah Seo; Young Min Lee; Hyun-Kyung Lee; Je Hyeong Kim; Chol Shin; Jong-Ryul Ghim; Jae-Gook Shin; Dong Hyun Kim
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

Review 3.  Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.

Authors:  Cheol Kyu Park; Yong Soo Kwon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-10-31

4.  Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.

Authors:  Elsje Pienaar; Jansy Sarathy; Brendan Prideaux; Jillian Dietzold; Véronique Dartois; Denise E Kirschner; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2017-08-17       Impact factor: 4.475

Review 5.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

6.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

7.  Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis.

Authors:  Catherine A Hogan; Lekha Puri; Genevieve Gore; Madhukar Pai
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-12-13

8.  Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.

Authors:  Yu-Tzu Tseng; Yu-Chung Chuang; Chin-Chung Shu; Chien-Ching Hung; Chiung-Fang Hsu; Jann-Yuan Wang
Journal:  Crit Care       Date:  2012-10-25       Impact factor: 9.097

9.  Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Authors:  Myriam V Valenzuela; Mirian Domenech; Patricia Mateos-Martínez; Fernando González-Camacho; Adela G de la Campa; Maria Teresa García
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.